Editorial Expression of LDLRs (Low-Density Lipoprotein Receptors), Dyslipidemia Severity, and Response to PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Inhibition in Homozygous Familial Hypercholesterolemia Connecting the Dots Raul D. Santos omozygous familial hypercholesterolemia (HoFH) is LDL-C in HoFH, it is uncertain whether this is affected by 4–7 Hcharacterized by extremely elevated low-density lipo- LDLR expression. In theory, LDLR expression and func- protein cholesterol (LDL-C) levels (usually 4–5-fold normal) tion should not influence LDL-C lowering by mipomersen and appearance of xanthomas, aggressive atherosclerotic car- (an apoB synthesis inhibitor) or lomitapide (a microsomal diovascular as well as aortic and supra-aortic valve diseases, triglyceride transfer protein inhibitor) that reduce production before the age of 20 years. The severity of the HoFH phe- of LDL precursors (Figure), and this seems to be the case from notype and its ominous consequences correlate with LDL-C small numbers of patients in clinical trials treated with these levels. The latter are influenced primarily by the type of famil- newer agents. ial hypercholesterolemia (FH)-causing molecular defect. The Monoclonal antibodies against PCSK9, like alirocumab gravest phenotypes result from homozygous or compound and evolocumab, reduce PCSK9-mediated LDLR degrada- heterozygous mutations in the LDLR gene (low-density lipo- tion and consequently lower
Arteriosclerosis, Thrombosis, and Vascular Biology – Wolters Kluwer Health
Published: Mar 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera